Why I’m not selling5 Dec 2019 11:17
The launch soon of its first product, a wound care treatment, could see the shares double in value as the story de-risks and first sales are generated, the house suggested.
“Eventually, if the products deliver on their promising early results, we would expect interest from the global medtech companies, and if each product area works, we see the potential for Tissue to be a US$1bn company.”